Clinical trials · Pennsylvania
Ovarian cancer clinical trials in Pennsylvania
We’re tracking 78 recruiting ovarian cancer studies with a site in Pennsylvania — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT06276491RecruitingPhase 1
Safety study of an investigational drug for advanced cancer with the CLDN6 marker
This trial tests an investigational drug for people with advanced solid tumors, especially ovarian, fallopian tube, peritoneal, endometrial, or germ cell cancers that have a specific marker called CLDN6. The goal is to see if the drug is safe and tolerable.
Pittsburgh, PennsylvaniaAges 15 years+ - NCT07213804RecruitingPhase 3
Study of sofetabart mipitecan for ovarian cancer
This trial tests a new drug called sofetabart mipitecan for people with ovarian cancer that has come back after treatment. It is for those whose cancer is either resistant to platinum chemo (Part A) or sensitive to it (Parts B and C). The study will see if the drug can help shrink or slow the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04251052Recruiting
Compare two surgeries to lower ovarian cancer risk in BRCA1 carriers
This study compares two risk-reducing surgery plans for people with a BRCA1 genetic change to see which approach helps lower ovarian cancer risk. You may be asked to have the study procedure sooner or later depending on your chosen plan.
Abington, PennsylvaniaAges 35–50 - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07470853RecruitingPhase 1
Study of HWK-016 for advanced ovarian or endometrial cancer
This trial tests a new drug called HWK-016, which is designed to target and deliver medicine directly to cancer cells that have a specific marker (MUC16). It is for people with advanced ovarian or endometrial cancer to see if it can shrink tumors or slow their growth.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07546500RecruitingPhase 3
Azenosertib versus chemotherapy for advanced ovarian cancer
This trial tests a new drug called azenosertib against standard chemotherapy for ovarian, fallopian tube, or peritoneal cancer that has come back after platinum-based treatment. The drug targets a specific protein (cyclin E1) found in some tumors and may help stop cancer cells from dividing.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05287451Recruiting
Tube removal now, ovaries later for high cancer-risk women
This study looks at the safety of removing your fallopian tubes first (RRS) and delaying ovary removal (oophorectomy) to lower cancer risk. It focuses on women who carry certain inherited gene changes, and may help avoid earlier menopause for some people.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07078409Enrolling by invitation
Screening for ovarian cancer risk
This trial tests whether a nudge or reminder can help doctors refer patients with suspicious ovarian masses to a gynecologic oncologist. If you have a finding on an imaging test that suggests possible ovarian cancer, this study may help connect you with the right specialist.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04585958RecruitingPhase 1
DS-8201a plus olaparib for HER2-positive platinum-resistant ovarian cancer
This trial tests whether combining DS-8201a with olaparib can slow or shrink HER2-positive ovarian cancer that has returned quickly after platinum chemotherapy. It’s a Phase 1 study, meaning it mainly checks safety and finds the best dose, while also looking for signs of anti-cancer activity.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05128825RecruitingPhase 2
Test drug azenosertib for platinum-resistant ovarian cancer
This Phase 2 trial tests azenosertib to treat platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. It looks for whether the drug can shrink tumors and improve outcomes in people whose cancer has returned after platinum chemotherapy.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Allentown, PennsylvaniaAges 18–60 - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06756035RecruitingPhase 1
Testing CT-95 in advanced cancers with mesothelin
This trial tests a new drug (CT-95) for advanced cancers that have a marker called mesothelin. It's an early-phase study to see if the drug is safe and effective.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06962059Recruiting
Healthy volunteers with ovaries needed for study
This study is looking for healthy volunteers who still have their ovaries and have not had cancer or certain genetic mutations. Researchers want to learn more about ovarian health.
Philadelphia, PennsylvaniaAges 30–50 - NCT03854110RecruitingPhase 1
Testing a new drug for ovarian cancer that resists platinum chemo
This trial studies a new drug, misetionamide, given alone or with gemcitabine, for people with ovarian, fallopian tube, or primary peritoneal cancer that no longer responds to platinum-based chemotherapy. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
Phildelphia, PennsylvaniaAges 18 years+ - NCT04294927Recruiting
Tube removal first, then ovaries later for high-risk women
This study looks at whether removing the fallopian tubes first, and the ovaries later, is safe for women with certain inherited gene mutations that raise ovarian cancer risk. It may help you understand a prevention approach when you’re considered high risk and have finished having children.
Philadelphia, PennsylvaniaAges 25–50 - NCT04752826RecruitingPhase 1/Phase 2
Testing BI-1808 plus Keytruda for advanced cancers
This trial tests a new cancer medicine (BI-1808) either alone or together with Keytruda (pembrolizumab) in people with advanced cancers. It may help by strengthening the immune system’s attack on cancer, especially if standard treatments are no longer working or aren’t suitable.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06730347RecruitingPhase 2
Study of lorigerlimab for advanced ovarian and other cancers
This trial tests a new drug, lorigerlimab, for people with certain types of ovarian cancer or related cancers that have come back or not responded to treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT01870752Recruiting
Transplanting frozen ovarian tissue to help you try for pregnancy
This trial studies whether thawed, previously frozen ovarian tissue can be transplanted to help people with ovarian insufficiency become pregnant. It may help if you already have cryopreserved ovarian tissue stored and your care team feels you’re a good candidate for the procedure.
Philadelphia, PennsylvaniaAges 18–45 - NCT05950464RecruitingPhase 1
Dose study of two targeted drugs for recurrent ovarian cancer
This Phase 1 trial tests different doses of two study drugs (M1774 and ZEN-3694) for recurrent ovarian cancer and some recurrent endometrial cancers. It aims to find a safe dose and see how well the treatment works, especially in cancers with certain tumor features.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07115043RecruitingPhase 1/Phase 2
Study of AZD6750 for advanced solid tumors
This trial tests a new drug called AZD6750 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06161025RecruitingPhase 2/Phase 3
Raludotatug Deruxtecan for resistant ovarian cancer
This study tests a new drug called Raludotatug Deruxtecan (R-DXd) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if R-DXd can shrink tumors or slow cancer growth.
Philadelphia, PennsylvaniaAges 18 years+ - NCT02637934RecruitingPhase 1
PET scan tracer study for ovarian or related cancers
This early study tests a radioactive tracer (given as an injection) and tracks how it moves through the body using PET/CT scans. It may help doctors better understand how this tracer behaves in cancers of the ovaries, fallopian tubes, or the lining of the abdomen.
Philadelphia, PennsylvaniaAges 18 years+
Ovarian cancer trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting ovarian cancer studies listed above.
- University of Pennsylvania · 14 studies
- Thomas Jefferson University Hospital · 5 studies
- UPMC Hillman Cancer Center · 5 studies
- Asplundh Cancer Pavilion · 3 studies
- Allegheny General Hospital · 2 studies
- Christiana Care Health System-Concord Health Center · 2 studies
- Forbes Hospital · 2 studies
- Fox Chase Cancer Center · 2 studies
What taking part in a ovarian cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Ovarian cancer trials in other states
Common questions
- Are there ovarian cancer clinical trials in Pennsylvania?
- Yes. We're currently tracking 78 recruiting ovarian cancer studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a ovarian cancer study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New ovarian cancer studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.